Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PATADAY ONCE DAILY RELIEF vs AMPHOTEC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Treatment of ocular itching associated with allergic conjunctivitis (FDA-approved)
Treatment of progressive, potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, mucormycosis, sporotrichosis,Treatment of visceral leishmaniasis (off-label),Empiric therapy in febrile neutropenic patients (off-label),Treatment of primary amebic meningoencephalitis (off-label)
1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Terminal elimination half-life is approximately 9 hours; allows twice-daily dosing for sustained symptom control.
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Olopatadine undergoes minimal hepatic metabolism; approximately 60-70% excreted unchanged in urine. Metabolites include N-demethylated and N-oxide derivatives; CYP450 enzymes not significantly involved.
Metabolized minimally, if at all; elimination is primarily via unchanged drug excretion in urine and bile over a prolonged period.
Primarily renal excretion: approximately 60% of dose excreted unchanged in urine; fecal elimination accounts for less than 10%.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Approximately 70-80% bound to plasma proteins, primarily albumin.
>95% bound to albumin and alpha-1-acid glycoprotein.
Volume of distribution is approximately 1.4 L/kg, indicating distribution into total body water.
4.0 L/kg (large, indicates extensive tissue binding, especially in liver, spleen, and lungs).
Ocular bioavailability is low due to nasolacrimal drainage and systemic absorption; systemic bioavailability from ocular dose is less than 5%.
Not applicable (IV only); if oral, <5% (due to poor absorption and first-pass metabolism).
No dosage adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution as safety has not been established.
No dose adjustment required for renal impairment; however, monitor renal function closely during therapy.
No dosage adjustment required for mild to moderate hepatic impairment. For severe hepatic impairment (Child-Pugh class C), use with caution as safety has not been established.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
For children 2 years of age and older: 1 drop in each affected eye once daily. Safety and efficacy in children under 2 years have not been established.
5 mg/kg intravenously once daily; safety and efficacy not established in neonates.
No specific dosage adjustment required. Use the same dose as for younger adults. Overall, no differences in safety or efficacy were observed between elderly and younger patients.
No specific dose adjustment; monitor renal function and electrolyte levels due to age-related decline in renal function.
None.
This drug should be used primarily for treatment of patients with progressive, potentially life-threatening fungal infections; it is not intended for treatment of non-invasive fungal infections (e.g., oral thrush, vaginal candidiasis) in patients with normal neutrophil counts.
Not for injection; for topical ophthalmic use only.,Do not wear contact lenses if eyes are red; wait at least 10 minutes after instillation before inserting lenses.,Contains benzalkonium chloride which may be absorbed by soft contact lenses.,May cause transient stinging or burning upon instillation.
Nephrotoxicity: monitor renal function closely; risk increased with concurrent nephrotoxic drugs.,Infusion-related reactions: fever, chills, rigors, hypotension, dyspnea; premedicate as needed.,Electrolyte abnormalities: hypokalemia, hypomagnesemia; monitor levels and replace.,Hepatotoxicity: monitor liver function tests.,Cardiotoxicity: arrhythmias, especially with rapid infusion or hypokalemia.,Pulmonary toxicity: acute pulmonary edema (rare), especially in patients with low ejection fraction.
Hypersensitivity to olopatadine or any component of the formulation.
Hypersensitivity to amphotericin B or any component of the formulation (unless condition is life-threatening and amenable only to amphotericin therapy).
No known food interactions. No dietary restrictions required.
No specific food interactions. Ensure adequate hydration and electrolyte intake as directed. Avoid grapefruit juice as it may alter drug metabolism.
Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic doses. No adequate human studies exist. Risk cannot be ruled out; use only if benefit outweighs potential fetal risk.
Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use during the first trimester is not associated with a significant increase in congenital anomalies. During the second and third trimesters, there is no evidence of fetal toxicity, although the drug should be used only if clearly needed due to maternal systemic fungal infection.
Olopatadine is excreted in rat milk at concentrations ~2.4 times higher than maternal plasma. No human data on M/P ratio. Caution advised; consider risk-benefit and monitor infant for anticholinergic effects.
Amphotericin B is excreted into breast milk in low concentrations. The M/P ratio is unknown. It is considered compatible with breastfeeding because of poor oral bioavailability; however, caution is advised, and monitoring for infant diarrhea or thrush is recommended.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on available data. Use at lowest effective dose and shortest duration.
Pharmacokinetic changes in pregnancy (increased volume of distribution, altered clearance) may require dose adjustment. Standard dosing is 3-5 mg/kg/day IV, but serum concentrations should be monitored to ensure therapeutic levels without excessive toxicity. Dose may need to be increased by 25-50% in the third trimester.
Pataday Once Daily Relief contains olopatadine 0.2%, a mast cell stabilizer and antihistamine. For optimal efficacy, instruct patients to administer one drop in each affected eye once daily. Shake bottle before use. Wait at least 5 minutes before inserting contact lenses due to preservative (benzalkonium chloride). Monitor for transient burning or stinging upon instillation. Not for injection. Patients using additional ophthalmic products should separate by 5 minutes.
Amphotec (amphotericin B liposomal) is the preferred formulation for invasive fungal infections due to reduced nephrotoxicity compared to deoxycholate. Monitor for infusion-related reactions (fever, rigors, hypotension) and premedicate with acetaminophen, diphenhydramine, and hydrocortisone. Requires baseline and serial renal function, electrolytes (especially potassium, magnesium), and liver function tests. Do not use with other nephrotoxic drugs if possible. Electrolyte repletion is critical.
Do not touch dropper tip to any surface to avoid contamination.,Remove contact lenses before use; wait 10 minutes before reinserting.,May cause temporary blurred vision; avoid driving until vision clears.,If you miss a dose, use it as soon as remembered, but skip if near next dose.,Keep bottle tightly closed when not in use; store at room temperature.
This medication treats serious fungal infections and is given intravenously in a hospital setting.,You may experience fever, chills, or shaking during the infusion; these can be managed with premedications.,Kidney function and blood electrolyte levels will be monitored regularly.,Report any signs of allergic reaction (rash, itching, difficulty breathing) or symptoms of electrolyte imbalance (muscle cramps, weakness, irregular heartbeat).,Avoid taking other medications that can harm the kidneys (e.g., certain antibiotics, NSAIDs) without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PATADAY ONCE DAILY RELIEF vs AMPHOTEC, answered by our medical review team.
PATADAY ONCE DAILY RELIEF is a Ophthalmic Antiallergic Agent that works by Olopatadine is a selective histamine H1 receptor antagonist and mast cell stabilizer. It inhibits release of histamine and other mediators from mast cells, reducing allergic conjunctivitis symptoms.. AMPHOTEC is a Antifungal that works by Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PATADAY ONCE DAILY RELIEF and AMPHOTEC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PATADAY ONCE DAILY RELIEF is: 1 drop in each affected eye once daily. The ophthalmic solution is 0.2% (olopatadine hydrochloride).. The standard adult dose of AMPHOTEC is: Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PATADAY ONCE DAILY RELIEF and AMPHOTEC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PATADAY ONCE DAILY RELIEF is classified as Category C. Pregnancy Category C. In animal studies, olopatadine (0.4 mg/kg/day SC) produced no teratogenic effects but caused reduced fetal weight and delayed ossification at maternally toxic. AMPHOTEC is classified as Category C. Amphotericin B (AMPHOTEC) is classified as category B. Animal studies have not demonstrated fetal harm, but there are no adequate human studies in pregnant women. Inadvertent use d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.